# Dianthus Therapeutics, Inc.: Form 8-K, filed Feb 2, 2023

- Company: [Dianthus Therapeutics, Inc.](/companies/dnth.md) (CIK 1690585)
- Form: 8-K
- Filed: 2023-02-02
- Accepted by EDGAR: Feb 2, 2023, 17:02 ET
- Period: 2023-01-31
- Accession: 0001193125-23-022825
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/d445995d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/

## Items reported

- Item 3.01: Delisting notice
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/d445995d8k.htm

Filed Feb 2, 2023.
Source: SEC EDGAR, the filing index for accession 0001193125-23-022825. Last ingested by Listed: Nov 13, 2026, 16:49 ET. No prices; not investment advice.
